Medicinal Inorganic Chemistry: Metallotherapeutics for Chronic Diseases
Published Online: 15 DEC 2011
Copyright © 2011 John Wiley & Sons, Ltd. All rights reserved.
Encyclopedia of Inorganic and Bioinorganic Chemistry
How to Cite
Thompson, K. H. 2011. Medicinal Inorganic Chemistry: Metallotherapeutics for Chronic Diseases. Encyclopedia of Inorganic and Bioinorganic Chemistry. .
- Published Online: 15 DEC 2011
Metal-containing therapeutic agents designed for use in chronic disorders, such as gastrointestinal dyspepsia, bipolar disease, diabetes mellitus, osteoporosis, and arthritis, present additional challenges to the medicinal chemist. Beyond the immediate toxicity issues seen with acute disease treatments, chronic use of metallotherapeutic agents may result in metal ion accumulation or in gradually developing intolerance that can require discontinuation of the drug. Metallotherapeutic agents that have passed the rigorous testing required for chronic use include bismuth subsalicylates, for a variety of gastrointestinal disorders; lithium carbonate, for bipolar disease; lanthanum carbonate, for end-stage renal disease; strontium ranelate, for osteoporosis; and the gold-based antiarthritic, Auranofin™, although the last has fallen out of favor. Chromium picolinate is an approved nutritional supplement, a designation that allows less stringent testing than for new chronic-use drugs. Among those compounds not currently approved for clinical use, but showing promise, the copper – indomethacin and zinc – indomethacin complexes, for inflammation resulting from rheumatoid arthritis; vanadium compounds, for glucose- and lipid-lowering in type 2 diabetes mellitus; and selenium compounds, as possible cancer preventatives, are worthy of consideration.
- renal insufficiency;
- chromium nicotinate;
- copper indomethacin;
- vanadyl sulfate;
- type 2 diabetes mellitus;
- protein tyrosine phosphatase;
- insulin receptor tyrosine kinase;